Becker's Healthcare July 2, 2024
The FTC has launched a probe into Teva Pharmaceuticals over contested drug patents the company refuses to remove from a federal registry, The Washington Post reported July 1.
Last week, the FTC ordered Teva to turn over internal communications and financial data related to nearly two dozen patents for its asthma and COPD inhalers listed in the FDA’s Orange Book, according to documents obtained by the Post.
The FTC claims that Teva and other...
Today's Sponsors
Today's Sponsor